Clinical Studies & Research

Dr. Cox completed work as the principal investigator in this study evaluating the effectiveness of body contouring devices. The study began in November 2018 and ended in April 2019.

Dr. Cox completed work as the principal investigator on this multicenter, single-blind, randomized, controlled study of the safety and effectiveness of JUVÉDERM
VOLUMA® XC injectable gel for cheek augmentation using a cannula. Dr. Cox has long been an advocate for the safety and effectiveness of injecting with the use of a cannula rather than just a needle in the mid-face. This study began in February of 2018 and finished in October of 2018.

Dr. Cox has completed work as principal investigator for this study evaluating augmentation of soft tissue fullness in the lips. Dr. Cox found this new product to be unique and effective, and we’re hopeful it will become widely available to patients in the coming years. This study began in November 2017 and ended in June of 2019.

Dr. Cox finished work as the principal investigator for this study evaluating an existing neuromodulator, Botox.  The study evaluated tweaks in the treatment of moderate to severe glabellar lines (those vertical lines between the brow).  Dr. Cox enjoyed looking at an existing product with a new perspective. This study began in November of 2017 and ended in March of 2019.

Dr. Cox completed work as principal investigator in this follow-up to a recently completed study.  The follow-up “An Open Label, Multi-Center Trial to Assess the Safety of Single and Repeat Treatments of [product] for Injection for Treatment of Moderate to Severe Glabellar Lines” is an unblinded study with multiple treatments.   This new, Botox-like product is seeking registration for treatment of vertical lines between the eyebrows, and may eventually be the sixth injectable used to treat facial wrinkles and lines.  Each will be unique in some way, patients working with skilled injectors will benefit from the ability to match product characteristics to individual anatomy. It’s an interesting time in aesthetic medicine!   This study started in June 2017 and ended in December 2018.

Dr. Cox recently completed work as principal investigator for the study “A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multi-Center Trial to Evaluate the Efficacy and Safety of [product] for Injection to Treat Moderate to Severe Glabellar Lines”  This is another new, Botox-like product seeking registration for treatment of vertical lines between the eyebrows.  This is the third new product in as many years looking to displace market leader Botox in the treatment of facial lines.  Adding already registered Dysport and Xeomin to the mix means we’ll eventually have six (or more) injectables for treating facial lines.  Each of the products is unique in some way, and we’ve really enjoyed working with the manufacturers to identify which patients will most benefit from the characteristics of their product.  It’s an interesting time in aesthetic medicine!   This study began in November 2016 and just finished in December 2017.